Literature DB >> 15581719

[Quality assurance program for pain management after obstetrical perineal injury].

L Urion1, F Bayoumeu, C Jandard, B Fontaine, H Bouaziz.   

Abstract

INTRODUCTION: A quality insurance program has been set up in order to improve the relief of pain in patients with perineal injury after childbirth. PATIENTS AND METHODS: The program has been developed according to the French standards of accreditation. After elaboration of a referential, a first study (103 patients) allowed to evaluate the ongoing practices and to appreciate the pain intensities. After analysis of the results, an action strategy has been elaborated, with a brand new therapeutic standard and a pain-monitoring program for nurses. Six months later, a second study (105 patients) measured the efficiency of the accomplished actions. The statistic analysis used chi2 and Kruskal-Wallis tests and a multivariate analyse (p <0.05).
RESULTS: Several indicators led to conclude to the success of this program: analgesics prescribed systematically and earlier, best observance, larger utilisation of the NSAI, decrease of the analgesics requests, improvement of the satisfaction referred to the relief of pain. The multivariate analyse showed a risk twice as little as in the second study to have a 36th hour VAS score superior to four (p =0.03).
CONCLUSION: The apply of this quality insurance program allowed to improve the analgesia after obstetric perineal injuries. A few adaptations are needed, and also more formations of the medical and paramedical staff. The durability of the accomplished actions shall be evaluated in the future.

Entities:  

Mesh:

Year:  2004        PMID: 15581719     DOI: 10.1016/j.annfar.2004.09.010

Source DB:  PubMed          Journal:  Ann Fr Anesth Reanim        ISSN: 0750-7658


  1 in total

1.  The effect of preemptive pudendal nerve block on pain after anterior and posterior vaginal repair.

Authors:  Safoura Rouholamin; Mitra Jabalameli; Abedi Mostafa
Journal:  Adv Biomed Res       Date:  2015-07-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.